Fig. 9
FKBP51 inhibitor SAFit2 attenuates CCl4-induced liver fibrosis and injury. A Masson’s trichrome staining of livers after treatment with SAFit2 in CCl4-induced liver fibrosis. B Assessment of liver fibrosis score. C, D AST and ALT levels are reduced with SAFit2. E SAFit2 application reduced serum IL6 and NFκB, but no effect on IFN-γ level. F, G Western blotting revealed an increase in Parkin and pAKT expression in WT-CCl4 treated with SAFit2 mice. Graphs represent mean values ± SEM from 5–6 mice for each group. H Normalized ATP production from WT and KO MEF cells treated with SAFit2. Graph represents mean values ± SEM from 3 independent experiments. p values were determined by student’s unpaired t-test (F), one-way ANOVA (B–E) or two-way ANOVA (H) with the statistical significance labeled as follows: *as p < 0.05, **as p < 0.01, *** as p < 0.001 and **** as p < 0.0001. Key: WT, wild type; KO, Fkbp51 KO